Suppr超能文献

基于光学相干断层扫描模式的糖尿病性黄斑水肿眼内注射贝伐单抗的疗效。

Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.

机构信息

Department of Ophthalmology, Inje University Seoul Paik Hospital, Seoul, Korea.

出版信息

Ophthalmologica. 2011;226(3):138-44. doi: 10.1159/000330045. Epub 2011 Aug 3.

Abstract

AIM

To compare the effects of intravitreal bevacizumab on different morphologic patterns of diabetic macular edema (DME) classified using optical coherence tomography (OCT).

MATERIALS AND METHODS

Medical records for 65 eyes of 48 patients were retrospectively reviewed, and each subject was classified as one of three DME types according to the OCT features: diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD). Subjects were given three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 ml). The clinical course of best-corrected visual acuity (BCVA) with a logarithm of the minimum angle of resolution chart and central foveal thickness (CFT) using OCT was monitored for 12 months after the injections. On follow-up, injections were repeated if DME remained or was aggravated.

RESULTS

Of the 65 eyes with DME, 29 eyes were of the DRT type, 21 of the CME type, and 15 of the SRD type. Before the injection, CFT and BCVA were, respectively, 377.1 ± 145.9 μm and 0.54 ± 0.36 in the DRT type, 427.7 ± 143.1 μm and 0.59 ± 0.42 in the CME type, and 485.1 ± 187.1 μm and 0.65 ± 0.27 in the SRD type; there was no significant difference in CFT and BCVA between DME types (p > 0.05). At 6 months, the changes in BCVA and CFT differed significantly between OCT types (p < 0.05). At 12 months, changes in CFT and BCVA from baseline were not significantly different between groups (p > 0.05). The DRT type was associated with a greater reduction in the CFT and greater BCVA improvement than the CME or SRD types.

CONCLUSIONS

Three monthly injections of intravitreal bevacizumab seem to be effective treatment in the first 6 months, but the therapeutic effect is temporary and repeated injections of bevacizumab should be considered to maintain the therapeutic effect after 6 months. In addition, intravitreal injection of bevacizumab was more effective in the DRT type than in the CME or SRD types of DME.

摘要

目的

比较玻璃体内注射贝伐单抗对使用光学相干断层扫描(OCT)分类的不同形态糖尿病黄斑水肿(DME)的疗效。

材料与方法

回顾性分析 48 例 65 只眼的病历资料,根据 OCT 特征将每位患者分为弥漫性视网膜增厚(DRT)、囊样黄斑水肿(CME)、浆液性视网膜脱离(SRD)三种 DME 类型之一。所有患者均接受玻璃体腔内注射贝伐单抗(1.25mg/0.05ml),每月一次,共 3 次。注射后 12 个月,采用最小分辨角对数视力表和 OCT 测量中心黄斑厚度(CFT),监测最佳矫正视力(BCVA)的临床变化。如果 DME 持续或加重,则重复注射。

结果

65 只眼的 DME 中,29 只眼为 DRT 型,21 只为 CME 型,15 只为 SRD 型。注射前,DRT 型的 CFT 和 BCVA 分别为 377.1±145.9μm 和 0.54±0.36,CME 型为 427.7±143.1μm 和 0.59±0.42,SRD 型为 485.1±187.1μm 和 0.65±0.27,不同类型 DME 之间 CFT 和 BCVA 无显著差异(p>0.05)。6 个月时,OCT 类型间 BCVA 和 CFT 的变化有显著差异(p<0.05)。12 个月时,各组间 CFT 和 BCVA 与基线相比的变化无显著差异(p>0.05)。与 CME 或 SRD 型相比,DRT 型的 CFT 降低更明显,BCVA 改善更明显。

结论

玻璃体腔内注射贝伐单抗每月一次,连续 3 次,在最初的 6 个月内似乎有效,但疗效是暂时的,6 个月后应考虑重复注射贝伐单抗以维持疗效。此外,与 CME 或 SRD 型 DME 相比,玻璃体内注射贝伐单抗对 DRT 型 DME 更有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验